07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat: Final Phase IIIb data

Final data from 61 PAH patients who had an insufficient response to treatment with phosphodiesterase-5 (PDE-5) inhibitors alone or in combination with an endothelin receptor antagonist in the open-label, international Phase IIIb RESPITE trial...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat regulatory update

EMA’s CHMP recommended against the use of Adempas riociguat from Bayer to treat pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP). CHMP said the recommendation follows the early termination of the Phase II RISE-IIP trial...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

Adempas riociguat: Phase IIb discontinued

Bayer discontinued the double-blind, placebo-controlled, international Phase IIb RISE-IIP trial in 147 patients after the study’s IDMC observed that patients receiving Adempas were at a “possible increased risk for death and other serious adverse events”...
00:37 , May 13, 2016 |  BC Extra  |  Clinical News

Bayer halts Adempas trial on safety concerns

Bayer AG (Xetra:BAYN) said it stopped the 147-patient Phase IIb RISE-IIP study of Adempas riociguat to treat pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP) after the study's independent DMC "observed that patients receiving riociguat...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Soluble guanylate cyclase (sGC)

Renal disease INDICATION: Diabetic nephropathy Rat studies suggest activating sGC could help treat diabetic nephropathy. In a rat model of diabetic nephropathy, oral 0.3, 1, 3 and 10 mg/kg doses of an undisclosed sGC activator decreased urinary...
07:00 , Jul 27, 2015 |  BioCentury  |  Product Development

Ironwood's local notion

Ironwood Pharmaceuticals Inc. is exploring how tissue-specific distribution can give its products additional activity or different clinical profiles suitable for new indications. The company reported Phase I data last week for IW-1973, a stimulator of...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

Adempas riociguat regulatory update

Bayer said Japan approved a regulatory application to expand the label of Adempas riociguat to include treatment of pulmonary hypertension (PAH). The oral soluble guanylate cyclase (sGC) stimulator is approved in Japan to treat...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Bayer pharmaceuticals, other news

Bayer said it will focus on its life science businesses and spin out its material sciences division, Bayer MaterialScience, into a separate publicly listed company in the next 12-18 months. The pharma said the major...